Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Rangering i aksjer #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Aksjekurs
$62.49
Sist synkronisert: 2024-03-06
Markedsverdi
$2.52B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel RayzeBio, Inc. Common Stock (RYZB)

Kategori

Aksjeprishistorikk for RayzeBio, Inc. Common Stock (RYZB)
Høyeste sluttskurs: $62.49 den 2024-03-01

Laveste sluttskurs: $20.99 den 2023-09-01
Aksjeprishistorikk for RayzeBio, Inc. Common Stock fra 2023 til 2026
Årlig aksjeprisytelse
År Ytelse
2024 87.31%
2023 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.63 -12.65%
AU
$764.73 7.12%
CH